Terms ending in 2029
Every in-force patent on ImmunoGen, Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 8,119,813 | Method for Preparing Enantiomerically Enriched N-Carboxyanhydride In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 8,613,930 | Cross-Linkers and Their Uses In force · High confidence | ImmunoGen, Inc. | In force | High confidence | |
| US 9,061,995 | Cross-Linkers and Their Uses In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 9,498,541 | Cross-Linkers and Their Uses In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 10,494,431 | Cross-Linkers and Their Uses In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 11,046,762 | Cross-Linkers and Their Uses In force · Medium confidence | ImmunoGen, Inc. | In force | Medium confidence | |
| US 8,314,244 | Method for Preparing Activated Esters In force · High confidence | ImmunoGen, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.